Wall Street analysts forecast that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will post ($0.77) earnings per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for AMAG Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.83) and the highest estimate coming in at ($0.70). AMAG Pharmaceuticals posted earnings of $0.10 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 870%. The business is scheduled to announce its next earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full-year earnings of ($2.85) per share for the current financial year, with EPS estimates ranging from ($3.63) to ($2.07). For the next fiscal year, analysts forecast that the business will report earnings of ($2.60) per share, with EPS estimates ranging from ($4.23) to ($1.25). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). The company had revenue of $122.20 million for the quarter, compared to analyst estimates of $118.23 million. AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The business’s revenue was down 1.7% on a year-over-year basis. During the same period in the prior year, the company posted ($4.31) EPS.
AMAG has been the topic of a number of analyst reports. Zacks Investment Research lowered AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 target price on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, September 26th. BidaskClub downgraded AMAG Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 25th. Deutsche Bank set a $23.00 target price on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, September 20th. Finally, Cowen set a $19.00 target price on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, November 1st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $21.97.
A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in AMAG Pharmaceuticals by 6.0% during the 2nd quarter. Legal & General Group Plc now owns 67,795 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 3,827 shares during the period. Alps Advisors Inc. boosted its stake in AMAG Pharmaceuticals by 9.0% during the 2nd quarter. Alps Advisors Inc. now owns 49,816 shares of the specialty pharmaceutical company’s stock valued at $971,000 after purchasing an additional 4,096 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of AMAG Pharmaceuticals by 8.5% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 88,180 shares of the specialty pharmaceutical company’s stock worth $1,720,000 after acquiring an additional 6,883 shares during the period. Renaissance Technologies LLC lifted its position in shares of AMAG Pharmaceuticals by 0.5% in the 3rd quarter. Renaissance Technologies LLC now owns 1,648,500 shares of the specialty pharmaceutical company’s stock worth $32,970,000 after acquiring an additional 7,400 shares during the period. Finally, Meeder Asset Management Inc. lifted its position in shares of AMAG Pharmaceuticals by 590.9% in the 2nd quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock worth $174,000 after acquiring an additional 7,652 shares during the period.
Shares of NASDAQ AMAG opened at $18.21 on Thursday. The company has a current ratio of 2.86, a quick ratio of 2.72 and a debt-to-equity ratio of 0.34. The stock has a market cap of $621.30 million, a PE ratio of -3.19 and a beta of 0.23. AMAG Pharmaceuticals has a 52 week low of $11.95 and a 52 week high of $26.10.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades
Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.